ArticleInternational journal of general medicine2025
Association of Serum Irisin With Severity and Prognosis in Patients With Coronavirus Disease 2019: A Prospective Cohort Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- FNDC4 and FNDC5 Attenuate SARS-CoV-2 S1-Induced Inflammatory Responses in Human Adipose Tissue.European journal of clinical investigation · 2026Article
- Irisin Attenuates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension via Ubiquitin-Mediated Regulation of ENO1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Irisin attenuates SARS-CoV-2 entry into cells and cell damage in 2D and 3D cultures of human subcutaneous adipocytes.Endocrine connections · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Irisin is the cleaved form of fibronectin type III domain-containing protein 5 (FNDC5), which can confer antioxidant and anti-inflammatory effects. Several studies have revealed that irisin can alleviate lung injury and affect the pathology of coronavirus disease 2019 (COVID-19). The aim of this study was to assess the relationships of serum irisin with the severity and prognosis of COVID-19. Methods: A total of 328 COVID-19 patients were recruited. Peripheral blood samples were collected. The level of serum irisin was determined by ELISA. The associations of serum irisin with COVID-19 severity and prognosis were evaluated through linear and logistic regression models on the basis of a prospective cohort study. Results: Serum irisin levels were lower in severe patients than in mild patients. The level of serum irisin was gradually decreased with the worsening of COVID-19. Spearman correlation analysis revealed that serum irisin concentration was inversely correlated with several clinical characteristics. Moreover, linear and logistic regression analyses revealed that serum irisin concentration was negatively correlated with the severity score. Interestingly, chronic heart and kidney diseases significantly affected the associations between serum irisin and severity scores. The results of the follow-up study suggested that the level of serum irisin upon admission was reduced in patients who died within one month of hospitalization. A lower serum irisin level at admission increased the risk of death within one month. Conclusion: Serum irisin levels at admission were negatively correlated with disease severity and prognosis, suggesting that irisin is involved in the pathological process of COVID-19. Serum irisin may be used as a biomarker for diagnostic and prognostic assessment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.